| Biosimilars and non-innovator biotherapeutics in India: An overview of the current situation. | |
| | |
MedLine Citation:
|
PMID: 21784652 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Globally, a large number of blockbuster biotherapeutic molecules are going off patent in the next few years. For emerging economies, like India, it is imperative to be able to provide safe and cost effective drugs for its huge, non-insured and poor population. India has a robust pharmaceutical industry including the biopharmaceutical sector which is actively engaged in the production and marketing of 'non-innovator' or 'copy' biotherapeutic products These products are approved through an abbreviated route which relies on limited safety and efficacy data enabling the local companies to keep the production costs low and pass on the price benefit to the patient and make the product affordable to the masses. Some of the available products may not be truly 'similar' and may be of suspect quality. The WHO [1] and the European Medicines Agency (EMA) [2] have published guidelines for the development and marketing of biosimilar products. These products, as stated in both guidelines undergo extensive head-to-head comparability testing with the reference biotherapeutic product (RBP) to show their similarity to the RBP in terms of quality, efficacy and safety. Regulators and administrators of different countries need to strike a balance in cost-to-benefit versus risks that are perceived for these products, keeping in mind global regulatory issues. |
| | |
Authors:
|
Hemant Malhotra |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-7-22 |
Journal Detail:
|
Title: Biologicals : journal of the International Association of Biological Standardization Volume: - ISSN: 1095-8320 ISO Abbreviation: - Publication Date: 2011 Jul |
Date Detail:
|
Created Date: 2011-7-25 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9004494 Medline TA: Biologicals Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Copyright Information:
|
Copyright © 2011 The International Alliance for Biologicals. Published by Elsevier Ltd. All rights reserved. |
Affiliation:
|
Division of Medical Oncology, SMS Medical College Hospital, C-70 Ram Marg Tilak Nagar, Jaipur 302004, India. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Reviewing non clinical data for a granulocyte colony stimulatory factor product: Experience in Brazi...
Next Document: Regulatory guidelines for biosimilar products in Korea.